Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 18/20 | 0.52 |
| ▸ | CHRM1 known ✓ | P11229 | 18/20 | 0.52 |
| ▸ | CHRM3 known ✓ | P20309 | 17/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4524905 | 0.94 | CHRM2 (0.55) | CHRM2CHRM1CHRM3SLC6A3KCNH2 | |
| Bromide SCHEMBL4515778 | 0.89 | CHRM2 (0.47) | CHRM2CHRM1CHRM3SLC6A3KCNH2 | |
| SCHEMBL6400842 | 0.85 | CHRM2 (0.62) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6401754 | 0.84 | CHRM2 (0.61) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4509625 | 0.84 | CHRM2 (0.63) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6399727 | 0.83 | CHRM2 (0.61) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6399684 | 0.81 | CHRM2 (0.66) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6401028 | 0.81 | CHRM2 (0.52) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6401869 | 0.80 | CHRM2 (0.51) | CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL6400235 | 0.80 | CHRM2 (0.52) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504432-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20070129397-A1 | Ester derivatives | MSD K.K. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7192969-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050065211-A1 | Ester derivatives | MSD K.K. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1302458-A1 | ESTER DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129397-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
| US-20050065211-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.